MS2
MCID: MLT093
MIFTS: 20

Multiple Sclerosis 2 (MS2)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Multiple Sclerosis 2

MalaCards integrated aliases for Multiple Sclerosis 2:

Name: Multiple Sclerosis 2 57
Multiple Sclerosis, Susceptibility to, 2 57 13
Ms2 57

Classifications:



External Ids:

OMIM® 57 612594
OMIM Phenotypic Series 57 PS126200

Summaries for Multiple Sclerosis 2

MalaCards based summary : Multiple Sclerosis 2, also known as multiple sclerosis, susceptibility to, 2, is related to triiodothyronine receptor auxiliary protein and multiple sclerosis. An important gene associated with Multiple Sclerosis 2 is MS2 (Multiple Sclerosis, Susceptibility To, 2). Affiliated tissues include spinal cord and eye.

More information from OMIM: 612594 PS126200

Related Diseases for Multiple Sclerosis 2

Diseases in the Multiple Sclerosis family:

Multiple Sclerosis 2 Multiple Sclerosis 3
Multiple Sclerosis 4 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis Primary Progressive Multiple Sclerosis

Diseases related to Multiple Sclerosis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Related Disease Score Top Affiliating Genes
1 triiodothyronine receptor auxiliary protein 10.4
2 multiple sclerosis 10.4
3 relapsing-remitting multiple sclerosis 10.2
4 hepatitis a 10.2
5 gastroenteritis 10.2
6 mouth disease 10.0
7 hepatitis e 10.0
8 hepatocellular carcinoma 10.0
9 human immunodeficiency virus type 1 10.0
10 chronic ulcer of skin 10.0
11 variola major 10.0
12 pleurisy 10.0
13 viral hepatitis 10.0
14 influenza 10.0
15 smallpox 10.0
16 autoimmune disease 9.8
17 bladder cancer 9.8
18 type 2 diabetes mellitus 9.8
19 schistosoma mansoni infection, susceptibility/ 9.8
20 australia antigen 9.8
21 celiac disease 1 9.8
22 cervical cancer 9.8
23 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
24 dengue virus 9.8
25 chops syndrome 9.8
26 helix syndrome 9.8
27 disease by infectious agent 9.8
28 rapidly involuting congenital hemangioma 9.8
29 trypanosomiasis 9.8
30 endocarditis 9.8
31 common cold 9.8
32 anogenital venereal wart 9.8
33 chagas disease 9.8
34 schistosomiasis 9.8
35 toxic shock syndrome 9.8
36 cholera 9.8
37 melanoma 9.8
38 papilloma 9.8
39 adenocarcinoma 9.8
40 early myoclonic encephalopathy 9.8
41 fibrosarcoma 9.8
42 gastric adenocarcinoma 9.8
43 lupus erythematosus 9.8
44 mitochondrial disorders 9.8
45 cytokine deficiency 9.8
46 recurrent respiratory papillomatosis 9.8
47 large granular lymphocyte leukemia 9.8
48 optic neuritis 9.8
49 neuritis 9.8
50 demyelinating disease 9.8

Graphical network of the top 20 diseases related to Multiple Sclerosis 2:



Diseases related to Multiple Sclerosis 2

Symptoms & Phenotypes for Multiple Sclerosis 2

Clinical features from OMIM®:

612594 (Updated 05-Apr-2021)

Drugs & Therapeutics for Multiple Sclerosis 2

Search Clinical Trials , NIH Clinical Center for Multiple Sclerosis 2

Genetic Tests for Multiple Sclerosis 2

Anatomical Context for Multiple Sclerosis 2

MalaCards organs/tissues related to Multiple Sclerosis 2:

40
Spinal Cord, Eye

Publications for Multiple Sclerosis 2

Articles related to Multiple Sclerosis 2:

(show top 50) (show all 86)
# Title Authors PMID Year
1
Risk alleles for multiple sclerosis in multiplex families. 57
19506219 2009
2
Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. 57
19155502 2009
3
Risk alleles for multiple sclerosis identified by a genomewide study. 57
17660530 2007
4
Surveillance Study of Acute Neurological Manifestations among 439 Egyptian Patients with COVID-19 in Assiut and Aswan University Hospitals. 61
33631765 2021
5
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. 61
33106389 2021
6
Aggressive multiple sclerosis (2): Treatment. 61
32530366 2020
7
Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports. 61
32120027 2020
8
[Development of an indicator set for the evaluation of the population-based integrated healthcare model 'Gesundes Kinzigtal' (Healthy Kinzigtal)]. 61
32467041 2020
9
Cognitive functions in pediatric multiple sclerosis: 2-years follow-up. 61
31913090 2020
10
Cerebrospinal fluid oligoclonal bands in Neuroborreliosis are specific for Borrelia burgdorferi. 61
32977328 2020
11
Therapeutic Outcome of Alemtuzumab in Korean Patients with Multiple Sclerosis: 2-Year Follow-Up. 61
31286704 2019
12
A Controlled Clinical Trial on the Effects of Exercise on Cognition and Mobility in Adults With Multiple Sclerosis. 61
29927751 2019
13
[Efficacy of botulinum toxin A injections in the urethral sphincter in patients with difficulties to perform self-intermittent catherization]. 61
29776876 2018
14
Impact of economic sanctions on access to noncommunicable diseases medicines in the Islamic Republic of Iran. 61
29658620 2018
15
Relationship between neuromuscular and perceived fatigue and locomotor performance in patients with multiple sclerosis. 61
27164538 2017
16
Perceived Exertion Is Lower When Using a Functional Electrical Stimulation Neuroprosthesis Compared With an Ankle-Foot Orthosis in Persons With Multiple Sclerosis: A Preliminary Study. 61
27680426 2017
17
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. 61
28183276 2017
18
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE. 61
28450894 2017
19
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. 61
26633184 2016
20
Impact of a Pelvic Floor Training Program Among Women with Multiple Sclerosis: A Controlled Clinical Trial. 61
25888662 2016
21
[A review of multiple sclerosis (2). Diagnosis and treatment]. 61
25442466 2015
22
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE. 61
25432952 2015
23
Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) - The Importance of Nutritonal Support in Patients with Head and Neck Cancers (HNCs) or Neurogenic Dysphagia (ND). 61
26011834 2015
24
Cognitive impairment and event-related potentials in paediatric multiple sclerosis: 2-year study. 61
21584740 2011
25
High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863). 61
19770795 2011
26
Analysis of the pathogenesis of experimental autoimmune optic neuritis. 61
20981263 2011
27
[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results]. 61
20964990 2010
28
Concurrent autoimmune diseases in patients with autoimmune hepatitis. 61
20087196 2010
29
Strategies used in the pursuit of achievability during goal setting in rehabilitation. 61
20065307 2010
30
Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. 61
19892770 2009
31
Plasma exchange for acute attacks of CNS demyelination: Predictors of improvement at 6 months. 61
19770470 2009
32
Lower urinary tract symptoms in women with multiple sclerosis: 2. 61
19717990 2009
33
The Physical Activity and Disability Survey -- Revised (PADS-R): an evaluation of a measure of physical activity in people with chronic neurological conditions. 61
19447843 2009
34
Subcutaneous Interferon Beta-1a Has a Positive Effect on Cognitive Performance in Mildly Disabled Patients with Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the COGIMUS Study. 61
21180642 2009
35
Natalizumab for multiple sclerosis? 61
18784381 2008
36
Multiple sclerosis: interferon beta for some serious forms. 61
18092425 2007
37
Tweak and FN14 in central nervous system health and disease. 61
17485258 2007
38
Involvement of membrane channels in autoimmune disorders. 61
17692013 2007
39
Hematopoietic stem cell transplantation in multiple sclerosis: experimental evidence to rethink the procedures. 61
15261562 2004
40
What makes it so hard? Barriers to health promotion experienced by people with multiple sclerosis and polio. 61
14724504 2004
41
Does trauma trigger multiple sclerosis? 2: A medicolegal view. 61
14671875 2003
42
Longitudinal study of cognitive dysfunction in multiple sclerosis: neuropsychological, neuroradiological, and neurophysiological findings. 61
12810771 2003
43
[Anxiety and physical limitation: a complex relation]. 61
12091780 2002
44
Changes in lymphocytic cluster distribution during extracorporeal immunoadsorption. 61
11879242 2002
45
Molecular and cellular analyses of HLA class II-associated susceptibility to autoimmune diseases in the Japanese population. 61
24383685 2001
46
[Superiority of interferon beta-1b in comparison with interferon beta-1a in multiple sclerosis. 2 years outcomes reveal that clinical advantages increase over time]. 61
11858146 2001
47
Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required. 61
11067719 2000
48
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. 61
10733998 2000
49
[Multiple sclerosis 2]. 61
11930375 1999
50
[Treatment of multiple sclerosis--2. Application of a new immunological basic research is close]. 61
9863301 1998

Variations for Multiple Sclerosis 2

Expression for Multiple Sclerosis 2

Search GEO for disease gene expression data for Multiple Sclerosis 2.

Pathways for Multiple Sclerosis 2

GO Terms for Multiple Sclerosis 2

Sources for Multiple Sclerosis 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....